Newer drugs for the treatment of hepatitis B viral infection


  • Sreelakshmi Venugopal Department of Pharmacology, Government Medical College, Thrissur, Kerala, India
  • Dhanya Thirookaran Harichandran Department of Pharmacology, Government Medical College, Thrissur, Kerala, India
  • K. B. SanalKumar Department of Pharmacology, Government Medical College, Manjeri, Kerala, India
  • M. B. Sujatha Department of Pharmacology, Government Medical College, Thrissur, Kerala, India



Hepatitis B, Viral infection, Pharmacotherapy


One of the main disadvantages of hepatitis B virus treatment is the persistence of the virus even after treatment. The main causes of this viral persistence can be an inadequacy of the immune function as well as some viral factors. The currently available drugs for hepatitis B are five oral nucleoside/nucleotide analogs (lamivudine, adefovir dipivoxil, tenofovir, entecavir, telbivudine) and two interferon drugs (interferon alfa-2b, pegylated interferon alfa-2a). However, these therapies do not lead to sustained remission, requiring indefinite treatment as viral load frequently rebounds once suppressive therapy is stopped.


Ward H, Tang L, Poonia B, Kottilil S. Treatment of hepatitis B virus: an update. Future Microbiol. 2016;11(12):1581-97.

Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. Journal of hepatology. 2016;64(1):S117-31.

Wang XY, Chen HS. Emerging antivirals for the treatment of hepatitis B. World journal of gastroenterology. 2014;20(24):7707.

Painter GR, Almond MR, Trost LC, Lampert BM, Neyts J, De Clercq E, et al. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy) propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrobial agents and chemotherapy. 2007;51(10):3505-9.

Kaneko M, Watashi K, Kamisuki S, Matsunaga H, Iwamoto M, Kawai F, et al. A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide. Journal of virology. 2015;89(23):11945-53.

Boucle S, Lu X, Bassit L, Ozturk T, Russell OO, Amblard F, et al. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. Bioorganic & medicinal chemistry letters. 2017;27(4):904-10.

Vaillant A. Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Antiviral research. 2016;133:32-40.

Lopatin U. Drugs in the pipeline for HBV. Clinics in liver disease. 2019;23(3):535-55.

Gish RG, Yuen MF, Chan HLY, Given BD, Lai CL, Locarnini SA, et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res. 2015;121:97-108.

Guo F, Tang L, Shu S, Sehgal M, Sheraz M, Liu B, et al. Activation of stimulator of interferon genes in hepatocytes suppresses the replication of hepatitis B virus. Antimicrobial agents and chemotherapy. 2017; 61(10):e00771-17.

U. S. National Library of Medicine. Available at: Accessed 9 September 2020.




How to Cite

Venugopal, S., Harichandran, D. T., SanalKumar, K. B., & Sujatha, M. B. (2020). Newer drugs for the treatment of hepatitis B viral infection. International Journal of Basic & Clinical Pharmacology, 9(10), 1625–1626.



Letter to the Editor